eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) announced its participation in upcoming investor conferences, including a presentation at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8 at 12:10 PM EST and a Fireside Chat at the Stifel 2021 Virtual Healthcare Conference on November 17 at 3:20 PM EST. Webcasts of these events will be available on the company's website for 30 days post-event. eFFECTOR focuses on developing selective translation regulator inhibitors for cancer treatment, with its lead candidate, tomivosertib, in a Phase 2b trial for metastatic non-small cell lung cancer.

SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that management will participate in and host 1x1 meetings at the following upcoming investor conferences:

• Presentation at Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8^th at 12:10 PM EST
• Fireside Chat at Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17^th at 3:20 PM EST

A live webcast of each event will be available on the "Events and Presentation" page of the Investors section of the Company’s website. A replay of the webcasts will be available for 30 days following the event. For more information, please visit investors.effector.com.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.

Contacts:

Investors:
Stephanie Carrington
ICR Westwicke
646-277-1282
Stephanie.Carrington@westwicke.com 

Media:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi.chokeir@canalecomm.com 

FAQ

What investor conferences is eFFECTOR Therapeutics participating in November 2021?

eFFECTOR Therapeutics will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8 at 12:10 PM EST and hold a Fireside Chat at the Stifel 2021 Virtual Healthcare Conference on November 17 at 3:20 PM EST.

Where can I watch the webcasts for eFFECTOR Therapeutics' upcoming conferences?

The webcasts for eFFECTOR Therapeutics' upcoming conferences will be available on the 'Events and Presentation' page of the company's Investors section for 30 days after each event.

What is the lead product candidate of eFFECTOR Therapeutics?

The lead product candidate of eFFECTOR Therapeutics is tomivosertib, a MNK inhibitor currently evaluated in a Phase 2b trial for metastatic non-small cell lung cancer.

What types of diseases does eFFECTOR Therapeutics focus on treating?

eFFECTOR Therapeutics focuses on the development of oncology drugs targeting cancer, specifically through selective translation regulator inhibitors.

What collaborations does eFFECTOR Therapeutics have for drug development?

eFFECTOR Therapeutics has a global collaboration with Pfizer to develop inhibitors targeting eIF4E, in addition to its ongoing research on antiviral therapy for COVID-19.